Agios Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 505,617 shares at the public offering price of $44.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $173 million.
The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
